



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/466,921	06/06/95	ALIZON	M 03459.0008-0 <sup>mk</sup>

FINNEGAN HENDERSON FARABOW  
GARRETT AND DUNNER  
1300 I STREET NW  
WASHINGTON DC 20005-3315

HM22/0316

EXAMINER

PARKIN, J

ART UNIT

PAPER NUMBER

1648

26

DATE MAILED:

03/16/99

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

# Office Action Summary

Application No.  
08/466,921

Applicant(s)  
Alizon et al.

Examiner  
Jeffrey S. Parkin, Ph.D.

Group Art Unit  
1648



☒ Responsive to communication(s) filed on 10 Dec 1998

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claims

☒ Claim(s) 39-61 is/are pending in the application.

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

☒ Claim(s) 39-52 is/are allowed.

☒ Claim(s) 53-61 is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

☒ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☒ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been

☒ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☒ Notice of References Cited, PTO-892

☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). 6.5 (06/24/96)

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Serial No.: 08/466,921  
Applicants: Alizon et al.

Docket No.: 3495.0008-09  
Filing Date: 06/06/95

**Response to Submission Pursuant  
to 37 C.F.R. § 1.129(a)**

***Status of the Claims***

1. Since this application is eligible for the transitional procedure of 37 C.F.R. § 1.129(a), and the fee set forth in 37 C.F.R. § 1.17(r) has been timely paid, the finality of the previous Office action is hereby withdrawn pursuant to 37 C.F.R. § 1.129(a). Applicants' submission after final filed on 17 August, 1998, has been entered. Acknowledgement is hereby made of the Amendment submitted 10 December, 1998, wherein claims 28, 29, and 32-38 were canceled without prejudice or disclaimer, and new claims 46-61 submitted. Claims 39-61 are pending in the instant application.

***Information Disclosure Statement***

2. The information disclosure statement (Paper No. 6.5) filed 24 June, 1996, has been placed in the application file and the information referred to therein has been considered.

***35 U.S.C. § 112, First Paragraph***

3. The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Newly submitted claims 53-61 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at

the time the application was filed, had possession of the claimed invention. *In re Rasmussen*, 650 F.2d 1212, 211 U.S.P.Q. 323 (C.C.P.A. 1981). *In re Wertheim*, 541 F.2d 257, 191 U.S.P.Q. 90 (C.C.P.A. 1976). Applicants have submitted claims directed toward  
5 HIV-1 DNA fragments that hybridize to  $\lambda$ J19 restriction fragments under non-stringent hybridization conditions comprising 20% formamide, 8X SSC, at a temperature 37°C, followed by washing conditions of 2X SSC, 0.1% SDS, at a temperature 37°C. Although the disclosure describes such hybridization conditions, these  
10 conditions are discussed in reference to hybridization assays performed between three isolated LAV cDNA clones (e.g.,  $\lambda$ J19,  $\lambda$ J27, and  $\lambda$ J81) and cloned HTLV-II DNA (see pages 11 and 12 of the disclosure). Thus, the purpose of this hybridization assay was to assess the genetic relatedness of the recently identified LAV cDNA  
15 clones to that of other known retroviruses (e.g., HTLV-II). Moreover, the claims encompass an exceedingly large genus of nucleic acids encompassing small fragments from 10-15 nt to full-length proviral genomes (~10 kb). However, the disclosure fails to describe any other nucleic acids with the exception of those  
20 specific  $\lambda$ J19,  $\lambda$ J27, and  $\lambda$ J81 restriction fragments provided. The disclosure does not provide restriction maps or nucleotide sequences from any other HIV-1 isolate. The disclosure does not describe hybridization assays involving  $\lambda$ J19 restriction fragments and other HIV-1 clones. Accordingly, the skilled artisan, upon  
25 perusal of the specification, would not reach the conclusion that applicants' contemplated isolating and purifying other HIV-1 restriction fragments, particularly those that hybridize with the identified  $\lambda$ J19 restriction fragments under the precise conditions claimed. Accordingly, applicants have not met their burden  
30 pertaining to this aspect of § 112. See also *Bigham v. Godtfredsen*, 857 F.2d 1415, 8 U.S.P.Q.2d 1266 (Fed. Cir. 1988),

wherein the court concluded that the disclosure of an earlier compound was insufficient to provide an adequate written description for later claimed variants of this compound.

5        5. Claims 53-61 are rejected under 35 U.S.C. § 112, first paragraph, because the specification does not reasonably enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. Newly submitted claims  
10       53-61 are directed toward any HIV-1 restriction fragment that is capable of hybridizing to the indicated  $\lambda$ J19 restriction fragment under the recited conditions. These claims encompass nucleic acids obtained from any HIV-1 isolate of greatly differing sizes (i.e., a small restriction fragment of 100 nt would be capable of  
15       hybridizing, as well as, a proviral insert (~10 kb) released from a cloning vector). The disclosure provides preliminary restriction maps of LAV cDNA (e.g., pLAV75, pLAV82 and pLAV13) and lambda phage clones (e.g.,  $\lambda$ J19 and  $\lambda$ J81) (refer to Figures 1 and 2). The restriction coordinates are disclosed on page 4, as well as a  
20       series of restriction fragments believed to correspond to the *gag*, *pol* and *env* coding regions (e.g., *Pst*I (800 nt)/*Kpn*I (3500 nt); *Kpn*I(3,500 nt)/*Bgl*III (6,500 nt); *Kpn*I (6,100)/*Bgl*III (9150)). The specification does not disclose, *ipsis verbis*, HIV/LAV viral clones or restriction fragments obtained from any other viral isolate that  
25       are capable of hybridizing under the claimed, or any other conditions.

      The legal considerations that govern enablement determinations pertaining to undue experimentation are disclosed in *In re Wands*, 8 U.S.P.Q.2d 1400 (C.A.F.C. 1988) and *Ex parte Forman* 230 U.S.P.Q. 546 (PTO Bd. Pat. App. Int., 1986). The courts concluded that  
30       several factual inquiries should be considered when making such

assessments including the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims. *In re Rainer*, 52 C.C.P.A. 1593, 347 F.2d 574, 146 U.S.P.Q. 218 (1965). The disclosure fails to provide adequate guidance pertaining to a number of these considerations as follows:

1) The disclosure fails to provide an adequate written description of nucleic acids obtained from any other HIV-1 isolate, with the exception of the identified LAV restriction fragments. The specification only details the isolation of a small number of lamda phage clones all corresponding to the same viral isolate, LAV-1. However, the specification is silent pertaining to the identification and molecular characterization of any other HIV-1 isolates.

2) The disclosure fails to provide a sufficient number of working embodiments to enable the breadth of the claimed invention. As discussed in the preceding section, the disclosure only details the identification and preliminary restriction analysis of a small number of lambda phage clones derived from a single HIV-1 isolate designated LAV. The disclosure is silent pertaining to the inclusion of working examples detailing the identification and preliminary characterization of any single HIV-1 isolate other than LAV.

3) The prior art teaches that the *Lentivirinae* exist as a quasispecies and display considerable genotypic variability (Goodenow et al., 1989; Holland et al., 1992; and Gao et al., 1994). Accordingly, the skilled artisan cannot, *a priori*, predict the restriction map or nucleotide sequence of any given HIV-1 isolate.

4) The breadth of the claimed invention encompasses an exceedingly large genus of nucleic acids that are simply not supported by the disclosure. The mere recitation of a small number of species is insufficient to provide adequate support for a large genus of compounds, particularly in arts where considerable unpredictability exists. *Bigham v. Godtfredsen*, 857 F.2d 1415, 8 U.S.P.Q.2d 1266 (Fed. Cir. 1988). *Fujikawa v. Wattanasin*, 39 U.S.P.Q.2d 1895 (C.A.F.C 1996). *University of California v. Eli Lilly and Co.*, 39 U.S.P.Q.2d 1225 (D.C. S.Ind. 1995).

5) Legal precedence dictates that nucleic acids must be precisely defined in the disclosure by the provision of sufficient structural and functional characteristics. *Fiers v. Revel*, 984 F.2d 1164, 25 U.S.P.Q.2d 1601 (Fed. Cir. 1993). *Fujikawa v. Wattanasin*, 39 U.S.P.Q.2d 1895 (C.A.F.C 1996). *University of California v. Eli Lilly and Co.*, 39 U.S.P.Q.2d 1225 (D.C. S.Ind. 1995). However, the disclosure is deficient as it pertains to a description of these structural characteristics.

When the aforementioned factors are considered *in toto*, it would clearly require undue experimentation to practice the claimed invention.

#### **Allowable Subject Matter**

6. Claims 39-52 appear to be free of the prior art and are allowable. Claims 60 and 61 would also be allowable with appropriate amendment of the claim language to reflect their dependence upon allowable claims 46-52.


#### **Correspondence**

7. Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703)

308-4242 or (703) 305-3014. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 308-4426. Applicants are encouraged to notify the Examiner prior to the submission of such documents to facilitate their expeditious processing and entry.

8. Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (703) 308-2227. The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Chris Eisenschenk, J.D., Ph.D., can be reached at (703) 308-0452. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Respectfully,

  
Jeffrey S. Parkin, Ph.D.  
Patent Examiner  
Art Unit 1648

13 March, 1999

  
LAURIE SCHEINER  
PRIMARY EXAMINER